MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

About this update from Mira Pharmaceuticals, Inc.

[{"type":"text","content":"MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief.","length":537,"tagName":"p"},{"type":"text","content":""The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA," stated Erez Aminov, Chairman and CEO of MIRA. "By advancing two distinct formulations, we are positioning Ketamir-2 to address multiple pain conditions and broaden its potential applications. This strategic approach strengthens our presence in the pain management space and underscores our commitment to delivering innovative solutions while creating value for our shareholders."","length":549,"tagName":"p"},{"type":"text","content":"Expanding Therapeutic Potential with Topical Ketamir-2","length":54,"tagName":"p"},{"type":"text","content":"The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects. By offering localized relief, topical Ketamir-2 has the potential to transform the treatment landscape for neuropathic and inflammatory pain conditions, which currently lack effective long-term solutions.","length":387,"tagName":"p"},{"type":"text","content":"Potential applications include:","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Neuropathic Pain Conditions - Covers diabetic neuropathy, postherpetic neuralgia (shingles-related pain), chemotherapy-induced peripheral neuropathy (CIPN), and complex regional pain syndrome (CRPS)-all of which cause chronic nerve pain and significantly impact quality of life.","length":278,"tagName":"p"}]},{"val":[{"type":"text","content":"Inflammatory Pain Conditions - Includes osteoarthritis and rheumatoid arthritis, affecting millions of people worldwide and contributing to long-term disabili...

More updates from Mira Pharmaceuticals, Inc.